Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab with chemoradiation in unresectable Stage III NSCLC
NCT04203511Phase 3Withdrawn
- Sponsor
- Incyte
- Start
- Jul 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of retifanlimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Incyte. Primary endpoint: Progression-Free Survival at 3 years. Planned start Jul 2020; status: withdrawn.
02
Drugs
retifanlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04203511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203511.